Raymond James & Associates Durect Corp Transaction History

Raymond James & Associates

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Oct 25, 2022	SELL	$0.43 - $5.9 $21,070 - $289,100	-49,000 Reduced 18.6%	214,500 $124,000
Q4 2021 Feb 08, 2022	SELL	$0.9 - $1.31 $6,300 - $9,170	-7,000 Reduced 2.59%	263,500 $260,000
Q3 2021 Nov 02, 2021	BUY	$1.21 - $1.61 $13,310 - $17,710	11,000 Added 4.24%	270,500 $346,000
Q2 2021 Aug 11, 2021	BUY	$1.6 - $2.02 $24,000 - $30,300	15,000 Added 6.13%	259,500 $423,000
Q1 2021 May 14, 2021	BUY	$1.86 - $2.87 $122,760 - $189,420	66,000 Added 36.97%	244,500 $484,000
Q3 2020 Nov 04, 2020	SELL	$1.6 - $2.35 $240 - $352	-150 Reduced 0.08%	178,500 $305,000
Q2 2020 Jul 28, 2020	SELL	$1.33 - $2.76 $98,420 - $204,239	-74,000 Reduced 29.29%	178,650 $414,000
Q1 2020 Apr 21, 2020	SELL	$0.97 - $2.85 $124,499 - $365,797	-128,350 Reduced 33.69%	252,650 $392,000
Q4 2019 Feb 12, 2020	BUY	$1.69 - $3.8 $64,220 - $144,400	38,000 Added 11.08%	381,000 $1.45 Million
Q3 2019 Nov 07, 2019	SELL	$0.61 - $2.21 $12,200 - $44,200	-20,000 Reduced 5.51%	343,000 $631,000
Q2 2019 Aug 06, 2019	SELL	$0.51 - $0.86 $2,040 - $3,440	-4,000 Reduced 1.09%	363,000 $237,000
Q1 2019 May 06, 2019	BUY	$0.51 - $0.82 $6,885 - $11,070	13,500 Added 3.82%	367,000 $230,000
Q4 2018 Feb 11, 2019	BUY	$0.48 - $1.1 $169,680 - $388,850	353,500 New	353,500 $171,000

593K

Ticker DRRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 227,794,000
Market Cap $194M
Description
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogeno...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.